Perform Another (Advanced) Search

1.  Study Posting (5030) Trial #160013, Cushing’s Disease, Escondido, CA
...Label Study of the Efficacy and Safety of CORLUX (mifepristone) in the Treatment of Endogenous Cushing’s Syndrome. A 6-month open-label Phase III multi-center clinical trial of CORLUX in ...
View Page

2.  CenterWatch: Clinical Trials in Category (651) Cushing’s Disease
...Label Study of the Efficacy and Safety of CORLUX (mifepristone) in the Treatment of Endogenous Cushing’s Syndrome. Jobson Medical Information • Privacy | • Glossary Copyright © 1995-2010 Jobson Medical Information LLC. Designed by ...
View Page

3.  Study Posting (5306) Trial #153364, Hypertension (High Blood Pressure), Costa Mesa, CA
...defined as 11PM to 7AM) • Have secondary hypertension of an etiology (eg, renovascular disease, pheochromocytoma, Cushing’s Syndrome) • Have recent history (within last 6 months) of myocardinal infarction, heart failure, unstable angina ...
View Page

4.  Study Posting (4036) Trial #94715, Diabetes Mellitus, Type 2, Hollywood, FL
...diabetes that is a result of pancreatic injury, or secondary forms of diabetes, e.g., Cushing’s syndrome and acromegaly. • Acute metabolic diabetic complications such as ketoacidosis or hyperosmolar state(coma) within ...
View Page

5.  Study Posting (3716) Trial #158772, Hypertension (High Blood Pressure), Waterbury, CT
...Heart Failure, Cerebrovascular Accident or Transient Ischemic Attack within the last 12 months • Renal Disease • Cushing's Syndrome • Subjects currently taking nitrates Cheryl Nickles, Patient Recruitment Coordinator Chase Medical Research, LLC 500 ...
View Page

6.  Study Posting (2424) Trial #81046, Amenorrhea, Boston, MA
...depression or other psychiatric disease, anemia) • Other endocrine causes of amenorrhea (hyperprolactinemia, hypothyroidism or hyperthyroidism, Cushing’s syndrome, congenital adrenal hyperplasia, polycystic ovarian syndrome, primary ovarian failure) • On medications known to affect ...
View Page

7.  CenterWatch Clinical Research Profile (5030) Trial #2059, AMCR Institute, Inc., Escondido, CA
...Label Study of the Efficacy and Safety of CORLUX (mifepristone) in the Treatment of Endogenous Cushing’s Syndrome. profileinquiry@centerwatch.com sponsors@amcrinstitute.com 2059 If you are interested in contacting this ...
View Page

8.  Newly Approved Drug Therapies (907) Verdeso (desonide), Connetics Corporation,
...of use. Systemic absorption of topical corticosteroids has produced reversible HPA axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. Verdeso Foam is contraindicated in subjects who are ...
View Page

9.  Newly Approved Drug Therapies (937) Desonate (desonide), Dow Pharm,
...HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of ...
View Page